Immuneering Corp (IMRX) income statement
IMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.38−0.07 (-2.03%)
Close on Nov 20, 2026Market cap $218.90MP/E –Yield –
Immuneering Corp financial ratios
See a number that looks wrong?
Close on Nov 20, 2026Market cap $218.90MP/E –Yield –
See a number that looks wrong?
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Margins | |||||||
| Gross margin | – | – | – | 50.1% | 44.6% | 44.6% | – |
| Operating margin | – | – | – | -16,325.8% | -1,629.2% | -739.0% | – |
| Pre-tax margin | – | – | – | -15,937.3% | -1,627.1% | -737.2% | – |
| Net profit margin | – | – | – | -15,937.3% | -1,612.3% | -737.2% | – |
| Free cash flow margin | – | – | – | -14,148.4% | -1,486.2% | -634.8% | – |
| Returns on capital | |||||||
| Return on equity | -43.1% | -92.5% | -53.4% | -38.0% | -50.2% | 117.5% | – |
| Return on assets | -39.4% | -78.6% | -47.5% | -34.9% | -32.7% | -44.3% | – |
| Return on tangible assets | -41.4% | -86.4% | -50.7% | -36.8% | -35.1% | -44.3% | – |
| Return on capital employed | -44.5% | -91.6% | -55.9% | -37.6% | -34.4% | -47.2% | – |
| NOPAT | -$46.91M | -$50.62M | -$46.15M | -$40.88M | -$26.77M | -$13.50M | – |
| Cash flow quality | |||||||
| OCF / Sales | – | – | – | -13,914.2% | -1,483.2% | -632.5% | – |
| OCF / Net income | 0.81 | 0.90 | 0.92 | 0.87 | 0.92 | 0.86 | – |
| FCF / OCF | 100.3% | 100.2% | 100.7% | 101.7% | 100.2% | 100.4% | – |
| FCF / Net income | 0.81 | 0.90 | 0.92 | 0.89 | 0.92 | 0.86 | – |
| FCF / EBITDA | 77.0% | 86.5% | 84.9% | – | – | – | – |
| Unlevered free cash flow | -$45.49M | -$55.08M | -$49.31M | -$44.84M | -$30.91M | -$14.67M | – |
| Levered free cash flow | -$45.49M | -$55.08M | -$49.31M | -$44.84M | -$30.91M | -$14.67M | – |
| Efficiency | |||||||
| Asset turnover | – | – | 0.00 | 0.00 | 0.02 | 0.06 | – |
| Fixed asset turnover | – | – | 0.00 | 0.29 | 4.77 | 35.91 | – |
| Receivables turnover | – | – | 0.00 | 2.45 | 5.58 | 4.62 | – |
| Days sales outstanding | – | – | – | 148.8 | 65.5 | 79.0 | – |
| Payables turnover | – | – | 0.00 | 0.07 | 0.80 | 0.86 | – |
| Days payables outstanding | – | – | – | 5,250.2 | 455.0 | 422.1 | – |
| CapEx to revenue | – | – | – | 234.3% | 2.9% | 2.3% | – |
| CapEx to OCF | -0.31% | -0.15% | -0.70% | -1.7% | -0.20% | -0.37% | – |
| CapEx to depreciation | 0.44 | 0.24 | 1.06 | – | – | – | – |
| Liquidity | |||||||
| Current ratio | 17.50 | 5.28 | 11.35 | 13.50 | 27.04 | 16.73 | – |
| Quick ratio | 17.50 | 5.28 | 11.35 | 13.50 | 27.04 | 16.73 | – |
| Cash ratio | 12.77 | 4.82 | 10.92 | 13.10 | 26.48 | 16.44 | – |
| Working capital | $166.17M | $32.08M | $81.24M | $100.69M | $146.70M | $35.48M | – |
| Net current asset value | $162.74M | $28.26M | $77.08M | $96.23M | $141.61M | $34.93M | – |
| Leverage | |||||||
| Assets to equity | 1.06 | 1.27 | 1.13 | 1.11 | 1.07 | -1.71 | – |
| Goodwill / Assets | 2.9% | 12.7% | 6.5% | 5.5% | 4.0% | – | – |
| Intangibles to total assets | 3.0% | 13.4% | 6.9% | 5.8% | 4.3% | – | – |
| Per share | |||||||
| Revenue per share | – | – | 0.00 | 0.01 | 0.15 | 0.47 | – |
| EPS (basic) | -1.27 | -2.04 | -1.88 | -1.91 | -2.46 | -3.44 | – |
| EPS (diluted) | -1.27 | -2.04 | -1.88 | -1.91 | -2.46 | -3.44 | – |
| Book value per share | 4.96 | 1.38 | 3.19 | 4.16 | 11.46 | -4.54 | – |
| Tangible book value per share | 4.80 | 1.15 | 2.94 | 3.89 | 10.93 | -4.54 | – |
| Cash per share | 2.92 | 1.21 | 3.01 | 4.00 | 10.96 | 7.49 | – |
| Operating cash flow per share | -1.03 | -1.83 | -1.72 | -1.67 | -2.27 | -2.95 | – |
| Free cash flow per share | -1.03 | -1.84 | -1.74 | -1.70 | -2.27 | -2.96 | – |
| CapEx per share | 0.0032 | 0.0028 | 0.01 | 0.03 | 0.0045 | 0.01 | – |
| Valuation at period end | |||||||
| Market cap | $233.99M | $64.98M | $203.53M | $127.62M | $133.97M | – | – |
| Enterprise value | $6.43M | $14.32M | $106.28M | $10.42M | -$15.50M | – | – |
| P/S | – | – | – | 403x | 64.4x | – | – |
| P/B | 1.1x | 1.6x | 2.2x | 1.2x | 0.9x | – | – |
| P/TBV | 1.1x | 1.9x | 2.4x | 1.2x | 0.9x | – | – |
| P/Gross profit | – | – | – | 803x | 145x | – | – |
| P/OCF | -5.2x | -1.2x | -4.2x | -2.9x | -4.3x | – | – |
| EV/Sales | – | – | – | 32.9x | -7.5x | – | – |
| EV/Gross profit | – | – | – | 65.6x | -16.7x | – | – |
| EV/EBIT | – | – | – | – | 0.5x | – | – |
| EV/OCF | -0.1x | -0.3x | -2.2x | -0.2x | 0.5x | – | – |
| EV/FCF | – | – | – | – | 0.5x | – | – |
| Earnings yield | -23.9% | -93.9% | -26.3% | -39.6% | -25.0% | – | – |
| FCF yield | -19.4% | -84.8% | -24.2% | -35.1% | -23.1% | – | – |
| Cost structure | |||||||
| R&D to revenue | – | – | – | 11,442.5% | 1,276.0% | 649.1% | – |
| Stock-based comp to revenue | – | – | – | 1,282.4% | 86.7% | 47.0% | – |
| Per employee | |||||||
| Total employees | 53 | 66 | 68 | 73 | 64 | 64 | 64 |
| Revenue per employee | – | – | $0 | $4.34K | $32.50K | $36.12K | – |
| Gross profit per employee | – | – | $0 | $2.18K | $14.48K | $16.11K | – |
| Operating profit per employee | -$1.12M | -$970.78K | -$859.01K | -$708.83K | -$529.47K | -$266.91K | – |
| Net income per employee | -$1.06M | -$924.80K | -$786.35K | -$691.97K | -$524.00K | -$266.25K | – |
| Free cash flow per employee | -$858.24K | -$834.61K | -$725.17K | -$614.30K | -$482.99K | -$229.29K | – |
| Growth | |||||||
| Revenue 1Y growth | – | – | -100.0% | -84.8% | -10.0% | – | – |
| Gross profit 1Y growth | – | – | -100.0% | -82.9% | -10.1% | – | – |
| EBIT 1Y growth | 7.3% | -9.7% | -12.9% | -52.7% | -98.4% | – | – |
| EBITDA 1Y growth | 7.3% | -9.7% | – | – | – | – | – |
| Net income 1Y growth | 8.2% | -14.1% | -5.9% | -50.6% | -96.8% | – | – |
| Diluted EPS 1Y growth | 37.7% | -8.5% | 1.6% | 22.4% | 28.5% | – | – |
| Operating cash flow 1Y growth | 17.6% | -12.3% | -11.0% | -42.9% | -111.0% | – | – |
| Free cash flow 1Y growth | 17.4% | -11.7% | -10.0% | -45.1% | -110.7% | – | – |
| CapEx 1Y growth | 67.6% | -75.2% | -53.8% | 1,121.5% | 13.8% | – | – |
| CapEx 3Y CAGR | -42.4% | 11.8% | 85.8% | – | – | – | – |
| CapEx 5Y CAGR | 21.6% | – | – | – | – | – | – |
| Total assets 1Y growth | 340.1% | -48.6% | -16.2% | -26.6% | 333.9% | – | – |
| Total assets 3Y CAGR | 23.8% | -31.9% | 38.7% | – | – | – | – |
| Total assets 5Y CAGR | 43.3% | – | – | – | – | – | – |
| Total equity 1Y growth | 427.9% | -54.3% | -17.5% | -29.6% | 793.8% | -244.4% | – |
| Total equity 3Y CAGR | 25.8% | -35.7% | – | – | – | – | – |
Every figure here is calculated from standardized financial statements — hover a row name for the formula — not reported by the company. Valuation multiples use the closing price at the end of that period, not today's price.